.png)
Public cloud works well for many biotech AI workloads, until scale starts exposing infrastructure limits. Storage throughput, GPU efficiency, data transfer costs, and compliance requirements can all become operational bottlenecks long before teams expect them to.
The decision in one page: the triggers that justify hybrid
If you run biotech AI workloads in the public cloud, you may be hitting limits. Data transfer costs can keep rising, GPU clusters can sit idle while waiting for data, and compliance teams may ask tough questions about where patient data lives.
Hybrid cloud means private infrastructure for sensitive workloads, plus selective cloud use for burst capacity. So, this is not about preference. Instead, it is about measurable thresholds where cloud-native setups stop working well.
Four triggers usually drive the move to hybrid:
- Cost breaking point: Data egress fees exceed 20% of compute spend
- Data gravity: Datasets over 500TB get reused weekly across training runs
- Performance bottlenecks: GPU utilization drops below 60% from I/O starvation
- Compliance boundaries: PHI or GxP data requires audit trails cloud can't guarantee
You do not need all four triggers. In many cases, one category hitting its threshold is enough to justify hybrid infrastructure.
Cost triggers: when cloud economics stop scaling
Cloud providers charge you to move data out of their systems. At first, these egress fees may look small. However, with biotech workloads, they can add up fast.
A common breaking point is when about 20% of your compute spend goes to data transfer. For instance, if you spend $100,000 per month on GPUs, paying $20,000 just to move data is hard to justify. At that point, it often costs less to keep data close to compute in private infrastructure.
In addition, steady GPU demand creates another key turning point. Organizations that use GPUs more than 100 hours per week often save money with dedicated hardware. The math is simple:
These figures assume $3 per GPU hour in the cloud versus amortized private infrastructure costs. The exact crossover point changes with each hardware generation. Still, when demand is steady, hybrid usually wins.
Data gravity triggers: which datasets must live near GPUs
Data gravity means that large datasets pull compute workloads toward them. Even with fast networks, moving a petabyte can take days. Because of that, model training that needs the same data over and over often works best when compute sits close to storage, rather than sending the data back and forth each time.
Biotech also creates very large datasets, such as:
- Genomics: Whole genome sequencing creates 100-200GB per sample
- Medical imaging: Digital pathology slides reach 1-5GB each
- Cryo-EM: Single particle analysis produces 5-10TB per dataset
- Multi-omics: Combined genomics, proteomics, and metabolomics data
In practice, the threshold is often around 500TB to 1PB of actively used data. Below that level, cloud storage with occasional transfers is usually manageable. Above that level, data movement time can slow research progress.
In hybrid setups, storage often follows a two-tier design. First, object storage holds full datasets for long-term retention. Then, a high-throughput tier near the GPUs caches active training data and checkpoints.
Performance triggers: how to tell if GPUs are starved
When GPUs sit idle while waiting for data, you waste money. Model FLOPS Utilization (MFU) shows what percent of the GPU’s theoretical performance you actually use during training. If MFU drops below 60% at scale, the cause is often an infrastructure bottleneck.
Another useful signal is step time variance. Training steps should finish in steady, predictable intervals. If timing jumps around a lot, it often means GPUs are waiting—sometimes for data, and sometimes for network communication.
Common causes of GPU starvation include:
- Small file bottlenecks: Genomics pipelines process millions of tiny files, overwhelming storage systems built for large reads
- Bandwidth limits: High-resolution medical imaging needs 40-80GB/s of storage throughput
- Checkpoint delays: Large models save 100GB+ checkpoints hourly, blocking training if writes are slow
- Network congestion: Distributed training needs consistent low-latency communication for gradient updates
Targets vary by workload. Even so, these general guidelines help you spot trouble:
- MFU above 60%: Indicates healthy utilization for most training
- Storage at 40GB/s per node: Keeps eight GPUs fed with data
- Network latency under 10 microseconds: Enables efficient distributed training
Compliance triggers: when regulated data forces a boundary
Regulations can create strict boundaries around biotech data. Protected Health Information (PHI) under HIPAA needs specific safeguards that many cloud setups cannot guarantee. Likewise, Good Manufacturing Practice (GxP) environments require validated systems with complete audit trails.
For many teams, 21 CFR Part 11 is a major reason to choose hybrid. This rule says that electronic records in pharmaceutical development must keep specific controls, including:
- Audit trails: Every data access, modification, and deletion logged permanently
- Access controls: Role-based permissions with documented workflows
- Data integrity: Validation that data stays unchanged from creation through archival
- Retention periods: Clinical trial data kept for 25 years after drug approval
These controls are often easier to meet in private infrastructure that you fully control. In that setting, you can know exactly where data lives, who can access it, and how long audit logs remain available.
Data residency adds another constraint. For example, European biotech companies must keep patient data within EU borders under GDPR. Also, some countries require genomic data from citizens to stay within the country. Private infrastructure makes data location clearer and more certain.
Consider this scenario. A clinical research organization runs Phase 3 trials and processes patient scans that count as PHI. They need audit logs for seven years, encryption keys that they alone control, and validation documents for regulatory submissions. Hybrid lets them keep PHI in validated private systems, while still using the cloud for non-sensitive work.
WhiteFiber fit: what we deliver for regulated hybrid
WhiteFiber provides infrastructure that supports regulated biotech hybrid workloads. Our facilities support high-density AI deployments ranging from roughly 50-150kW per rack with direct liquid cooling support.
We also connect storage, networking, and compute in a way that avoids bottlenecks. Storage architectures are designed to deliver the throughput required for GPU-dense workloads, with configurations capable of supporting tens to hundreds of GB/s depending on workload scale and topology.
We maintain SOC 2 Type II certified environments with operational controls designed to support audit and compliance requirements. Our facilities support HIPAA-aligned architectures with physical isolation, encryption key management, and controlled access models. As a result, organizations keep full control of their data, while we run the infrastructure.
The hybrid model connects private infrastructure with cloud resources. When demand spikes, workloads can burst from private clusters to public GPU capacity. At the same time, unified management covers both environments, so you avoid the complexity of running separate systems.
Our operational focus is built around outcomes:
- 99.95% uptime: For mission-critical workloads
- 24/7 engineering support: Direct access to infrastructure experts
- Transparent monitoring: Real-time visibility into power, cooling, and performance
This way, organizations get the control of private infrastructure, along with managed-service operational excellence.
FAQs: moving biotech workloads to hybrid
What dataset size and weekly reuse pattern justifies hybrid migration?
How do biotech organizations maintain GxP validation when migrating to hybrid infrastructure?
What specific GPU utilization metrics indicate storage or network bottlenecks rather than model limitations?
How do biotech teams move from cloud-only AI infrastructure to hybrid without disrupting active research pipelines?
.png)
.png)
